Jeffrey Wolf

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series
    Jeffrey Wolf
    Myeloma Program, Hematologic Malignancies, University of California, San Francisco, CA 94143 0324, USA
    Clin Adv Hematol Oncol 6:755-60. 2008

Collaborators

Detail Information

Publications1

  1. ncbi Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series
    Jeffrey Wolf
    Myeloma Program, Hematologic Malignancies, University of California, San Francisco, CA 94143 0324, USA
    Clin Adv Hematol Oncol 6:755-60. 2008
    ..Favorable observed response rates with bortezomib retreatment suggest that it may be a viable option for relapsed or refractory multiple myeloma, even in patients previously exposed to bortezomib...